• 1.大連友誼醫(yī)院外二科(大連116001);;
  • 2.安徽醫(yī)科大學(xué)第一附屬醫(yī)院普外科(合肥230022);

目的探討生長抑素對人胃癌細(xì)胞的抑制作用及其作用機(jī)理。方法以生長抑素類似物奧曲肽作用于人胃癌細(xì)胞株SGC7901細(xì)胞,以人成纖維細(xì)胞株HF作為正常細(xì)胞對照,以5FU作為陽性藥物對照,通過MTT實(shí)驗(yàn)、熒光顯微鏡觀察及流式細(xì)胞術(shù)分析,得出結(jié)論。結(jié)果一定濃度范圍內(nèi)的奧曲肽對SGC7901細(xì)胞產(chǎn)生抑制作用,其抑制作用具有量效關(guān)系和飽和性。奧曲肽對SGC7901細(xì)胞的抑制程度接近于5FU對他的抑制,而對HF細(xì)胞無影響。奧曲肽可誘導(dǎo)SGC7901細(xì)胞凋亡。結(jié)論奧曲肽在體外對SGC7901細(xì)胞具有抑制作用,誘導(dǎo)腫瘤細(xì)胞凋亡可能是其作用機(jī)理之一。

引用本文: 呂文才,耿小平,孟翔,凌譚,文翔. 奧曲肽對人胃癌細(xì)胞的凋亡誘導(dǎo)作用. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(3): 238-241. doi: 復(fù)制

1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [J]. Cancer, 1995; 76(6)∶ 961.
2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [J]. Am J Gastroenterol, 1998; 93(9)∶1468.
3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [J]. Ann Oncol, 1997; 8(10)∶1041.
4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [J]. Rev Med Interne, 1999; 20(5)∶421.
5. 鄭永唐,賁昆龍. 測定細(xì)胞存活和增殖的MTT方法的建立 [J]. 免疫學(xué)雜志, 1992; 8(4)∶266.
6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J]. Gut, 1996; 38(3)∶430.
7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [J]. Digestion, 1999; 60(Suppl 2)∶9.
8. 鄂征主編. 組織培養(yǎng)和分子細(xì)胞學(xué)技術(shù) [M]. 第1版. 北京: 北京出版社, 1995∶203~205.
9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [J]. Cancer, 1996; 78(1)∶35.
10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [J]. Cancer Res, 1998; 58(11)∶2375.
11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [J]. Int J Cancer, 1995; 60(5)∶694.
12. Reisine T. Somatostatin receptors [J]. Am J Physiol, 1995; 269(6 Pt 1)∶G813.
13. 吳蘇冬, 劉長利, 王慧川, 等. 參臼膠囊誘導(dǎo)肝癌SMMC7721細(xì)胞凋亡 [J]. 世界華人消化雜志, 2003; 11(7)∶908.
  1. 1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [J]. Cancer, 1995; 76(6)∶ 961.
  2. 2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [J]. Am J Gastroenterol, 1998; 93(9)∶1468.
  3. 3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [J]. Ann Oncol, 1997; 8(10)∶1041.
  4. 4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [J]. Rev Med Interne, 1999; 20(5)∶421.
  5. 5. 鄭永唐,賁昆龍. 測定細(xì)胞存活和增殖的MTT方法的建立 [J]. 免疫學(xué)雜志, 1992; 8(4)∶266.
  6. 6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J]. Gut, 1996; 38(3)∶430.
  7. 7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [J]. Digestion, 1999; 60(Suppl 2)∶9.
  8. 8. 鄂征主編. 組織培養(yǎng)和分子細(xì)胞學(xué)技術(shù) [M]. 第1版. 北京: 北京出版社, 1995∶203~205.
  9. 9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [J]. Cancer, 1996; 78(1)∶35.
  10. 10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [J]. Cancer Res, 1998; 58(11)∶2375.
  11. 11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [J]. Int J Cancer, 1995; 60(5)∶694.
  12. 12. Reisine T. Somatostatin receptors [J]. Am J Physiol, 1995; 269(6 Pt 1)∶G813.
  13. 13. 吳蘇冬, 劉長利, 王慧川, 等. 參臼膠囊誘導(dǎo)肝癌SMMC7721細(xì)胞凋亡 [J]. 世界華人消化雜志, 2003; 11(7)∶908.